- Aug. 27, 2020
-- Marinomed Biotech AG benefited from a surge in demand for Carragelose®
products in the first half of 2020. This increase, which began with the spread of COVID-19 in Europe, continues unchanged and will be reflected in revenues, especially in the second half of the year. In the first half of the year, Marinomed was able to increase revenues by 38% to a record EUR 2.28 million (1-6/2019: EUR 1.66 million).
"With tests in our own labs we showed that Carragelose®
is also an effective virus blocker against SARS-CoV-2. These results have now been confirmed by independent studies in the USA and Argentina", explains CEO Andreas Grassauer. Similar to antibodies, Carragelose®
can neutralize viruses and thus protect cells from infection. Andreas Grassauer continues:"With Carragelose®
we have a safe and highly effective product against SARS-CoV-2, which is already on the market in more than 40 countries. With our nasal sprays and throat products, we can already offer an excellent, immediately available treatment option and thus make an important contribution in the fight against the corona pandemic. Together with our sales partners and new product innovations, we will optimally use this enormous potential for further growth."http://www.marinomed.com
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of suchstatements or words such as "anticipate,"
"believe", "estimate", "expect", "intend", "plan", "project" and "target".Forward-
looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.